Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab plus carboplatin plus nabpaclitaxel (A plus CnP) Meeting Abstract
Industry Collaboration